| Nov 15 |
Purple Biotech GAAP EPS of -$0.39
|
| Nov 15 |
Purple Biotech Reports Third Quarter 2024 Financial Results
|
| Nov 5 |
Purple Biotech Unveils Promising Biomarker for Cancer Therapy
|
| Nov 4 |
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
|
| Oct 25 |
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Oct 11 |
Purple Biotech Unveils CAPTN-3 Cancer Therapy
|
| Oct 10 |
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Sep 18 |
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
|
| Sep 16 |
Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
